NON SMALL CELL LUNG CARCINOMA NSCLC
Clinical trials for NON SMALL CELL LUNG CARCINOMA NSCLC explained in plain language.
Never miss a new study
Get alerted when new NON SMALL CELL LUNG CARCINOMA NSCLC trials appear
Sign up with your email to follow new studies for NON SMALL CELL LUNG CARCINOMA NSCLC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for lung cancer: drug combo challenges chemo
Disease control OngoingThis study tested whether a combination of two immunotherapy drugs (durvalumab and tremelimumab) works better than standard chemotherapy for people with advanced lung cancer who haven't had treatment before. About 950 adults with a specific type of non-small cell lung cancer took…
Matched conditions: NON SMALL CELL LUNG CARCINOMA NSCLC
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated May 17, 2026 08:24 UTC
-
Immunotherapy shows promise as first defense against advanced lung cancer
Disease control OngoingThis study tests whether the immunotherapy drug durvalumab works better than standard chemotherapy as the first treatment for people with advanced non-small cell lung cancer that has high levels of a protein called PD-L1. About 669 adults with stage IV lung cancer, who have not h…
Matched conditions: NON SMALL CELL LUNG CARCINOMA NSCLC
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated May 17, 2026 08:20 UTC
-
Immunotherapy duo shows promise in lung cancer battle
Disease control OngoingThis study tested two immunotherapy drugs (durvalumab and tremelimumab) alone or together against standard chemotherapy for people with advanced non-small cell lung cancer who had not received prior treatment. Over 1,100 participants worldwide were enrolled. The main goals were t…
Matched conditions: NON SMALL CELL LUNG CARCINOMA NSCLC
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated May 07, 2026 18:43 UTC